HHS temporarily lets compounding pharmacies make six unapproved peptides
HHS said it will use "enforcement discretion" so compounding pharmacies can make six unapproved peptides while a formal rule change proceeds. Critics warn of untested products; HHS and Kennedy say it will steer people from the gray market.
1 / 2
The story, neutrally told
Mixed · 2The Department of Health and Human Services filed a notice on Wednesday giving compounding pharmacies a temporary green light to make six peptides while the agency continues work on a formal rule change. NBC NewsLC “The Department of Health and Human Services is giving compounding pharmacies a temporary green light to make six peptides while the agency continues to work on a formal rule change” Read at NBC News ↗ STATN “released a policy that will temporarily allow compounding pharmacies to manufacture some peptide products” Read at STAT ↗ Mixed · 2Under "enforcement discretion", HHS will not take action against state-licensed pharmacies, federal facilities or licensed physicians compounding the six peptides, which are BPC-157, epitalon, KPV, MOTS-c, semax and TB-500. STATN “HHS will use “enforcement discretion” to not take action against state-licensed pharmacies, federal facilities, or licensed physicians” Read at STAT ↗ NBC NewsLC “The six peptides are BPC-157, epitalon, KPV, MOTS-c, semax and TB-500.” Read at NBC News ↗ Left · 1NBC News reports that pharmacies can start offering them now, even though the peptides are not on the FDA's bulk drug substances list; adding an ingredient requires a proposed rule, public comment and a final rule, which can take several months. NBC NewsLC “these pharmacies can start offering them now, even though the peptides aren’t yet on the Food and Drug Administration’s list of ingredients compounding pharmacies are allowed to make.”“a process that can take several months” Read at NBC News ↗
Left · 1None of the six is FDA-approved, and NBC reports that the agency's own scientists concluded there is insufficient data to show they are safe and effective; they are promoted online for healing, younger-looking skin and longevity. NBC NewsLC “None are approved by the FDA, and the agency’s own scientists concluded there is insufficient data to prove they are safe and effective.” Read at NBC News ↗ Left · 1The FDA said compounders must certify the identity and purity of the compounds and must now report side effects, which was not previously required. NBC NewsLC “The FDA said compounding pharmacies must certify the identity and purity of the compounds. They must also now report side effects, which was not previously mandated.” Read at NBC News ↗ Mixed · 2In July an FDA advisory panel narrowly voted to recommend adding the six peptides to the bulk list; NBC notes the panel included six new appointees with ties to the peptide industry, and some members worried the recommendation could make it harder to refuse other unapproved drugs. NBC NewsLC “an FDA advisory panel narrowly voted in favor of adding six peptides to the bulk list.” Read at NBC News ↗ STATN “In July, an FDA advisory panel voted to recommend that these pharmacies be cleared to manufacture six of these substances.” Read at STAT ↗
Left · 1HHS spokesperson Emily Hilliard said the department is working to put prevention and patient safety at the center of health care, including confronting the risks of black-market peptides; Health Secretary Robert F. Kennedy Jr. and others argue compounding would move people away from a "gray market" of products labelled "for research use only". NBC NewsLC “Health Secretary Robert F. Kennedy Jr. and others have argued that allowing peptides to be compounded would move people away from this gray market and toward safer products.”“that includes confronting the risks of black-market peptides,” Emily Hilliard, an HHS spokesperson” Read at NBC News ↗ Left · 1Critics disagree: Peter Lurie of the Center for Science in the Public Interest said the FDA was "turning a blind eye", and Shabbir Safdar of the Partnership for Safe Medicines said the step would expose Americans to "untested dangerous substances". NBC NewsLC “the FDA was essentially “turning a blind eye” to widen access to drugs that have not been proven to work.”“would expose Americans to “untested dangerous substances.”” Read at NBC News ↗ Centre · 1STAT frames the move as increasing access to experimental wellness therapies embraced by the MAHA movement, noting there is little evidence for many of them. STATN “Kennedy and his MAHA movement have embraced peptides, though there's little evidence for many of the wellness compounds.” Read at STAT ↗
Every sentence links to the reporting it rests on. The pill in front of each says where its sources sit: Left, Centre or Right when one side supplies at least half of them, Mixed when they are evenly split. The number is how many outlets it cites.
Left1 outlet
- Framing
- Presents the move as a "shortcut" by Kennedy that bypasses the formal rulemaking process, with sceptical expert voices.
- Emphasis
- Lack of safety evidence, the industry ties of the advisory panel, and critics' warnings; also HHS's gray-market rationale.
- Leaves out or plays down
- Does not mention the MAHA movement framing.
- Charged language
- “shortcut”“turning a blind eye”“untested dangerous substances”
Centre1 outlet
- Framing
- Reports the policy as a straightforward HHS move that increases access to wellness therapies embraced by the MAHA movement, noting thin evidence.
- Emphasis
- Who is covered by the policy and the link to the July advisory panel.
- Leaves out or plays down
- Leaves out reactions, safety conditions and HHS's rationale.
- Charged language
- “experimental wellness therapies”
- For example
-
“increasing access to the experimental wellness therapies embraced by many in the MAHA movement” — STAT
Right0 outlets
No right outlet in our sources has covered this story yet.
What every side reports
- HHS is using enforcement discretion to temporarily allow compounding of six peptides.
- The move follows a July FDA advisory panel vote recommending the six peptides.
- The peptides are not FDA-approved.
Where accounts differ
-
Whether the policy makes peptides safer
- Left
- NBC reports HHS and Kennedy argue it would draw people from the gray market to safer products, while critics say it turns a blind eye and exposes people to untested substances.
- Centre
- STAT stresses increased access and little evidence for many of the compounds.
Department of Health and Human Services organisation
Says it is confronting the risks of black-market peptides and putting patient safety at the centre of care, while a formal rule proceeds.
“HHS is working to put prevention and patient safety at the center of health care” — NBC News
Robert F. Kennedy Jr. person
Has argued, with others, that allowing compounding would move people from the gray market to safer products; described as having embraced peptides.
“would move people away from this gray market and toward safer products.” — NBC News
“Kennedy and his MAHA movement have embraced peptides” — STAT
Left1 article
-
RFK Jr. takes shortcut to make some peptides more widely available
Critical Casts the policy as a shortcut around rulemaking, weighing HHS's gray-market argument against critics' safety warnings.
Centre1 article
-
STATN ·
STAT+: HHS moves to allow compounding of some unapproved peptides
Neutral Concise report of the policy and its scope, noting the MAHA embrace and thin evidence.
Right0 articles
No coverage yet.
- 28 Oct 16:13 First NBC NewsLC RFK Jr. takes shortcut to make some peptides more widely available
- 28 Oct 16:35 +21m STATN STAT+: HHS moves to allow compounding of some unapproved peptides
Times are when each article was published, or when we first saw it if the outlet gave no time.
Ask about this story
Loading…